Sio Capital Discloses 3.735M-Share Position in PMV Pharmaceuticals (13G/A)

Rhea-AI Filing Summary

PMV Pharmaceuticals (PMVP) reports that Sio Capital Management, LLC beneficially owns 3,735,396 shares of common stock, equal to 7.19% of the class. The filing states Sio has shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power, reflecting an adviser-managed position held for client funds.

The percentage is calculated using 51,952,680 shares outstanding as reported by the issuer. The filing notes Sio acts as investment adviser to affiliated funds that are the record owners and discloses that Sio GP, LLC and Michael Castor may be viewed as having influence, although any such beneficial ownership is expressly disclaimed. The statement also certifies the securities are held in the ordinary course of business and not to change or influence control.

Positive

• Beneficial ownership of 3,735,396 shares, representing 7.19% of PMV Pharmaceuticals common stock
• Shared voting and shared dispositive power over the reported shares, indicating authorized investment discretion
• Holdings are disclosed on Schedule 13G/A, consistent with passive/adviser-managed status

Negative

• No sole voting or dispositive power reported, so Sio lacks unilateral control over the securities
• Filing expressly disclaims intent to change or influence control, indicating no stated activist objective

Insights

Financial Analyst

TL;DR: Sio holds a material passive stake of 7.19% (3,735,396 shares) with shared voting/dispositive authority.

The Schedule 13G/A shows a meaningful equity position above the 5% disclosure threshold, signaling a sizable institutional holding in PMV Pharmaceuticals. The reporting person discloses shared voting and dispositive power and no sole control, consistent with an investment-adviser relationship managing client funds rather than an activist acquisition. The filing cites 51,952,680 shares outstanding as the basis for the 7.19% figure, providing a clear calculation for the ownership percentage.

Corporate Governance Expert

TL;DR: Disclosure reflects passive, adviser-led ownership; GP and named controller are referenced but beneficial ownership is expressly disclaimed.

The document identifies Sio as investment adviser to affiliated funds that directly hold the reported stock, and it clarifies that Sio GP, LLC and Michael Castor may be deemed to have influence though such ownership is disclaimed. The certification that the shares are held in the ordinary course and not to influence control reinforces a non-activist posture. From a governance perspective, the absence of sole voting or dispositive power limits unilateral influence despite the stake's material size.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

PMV Pharmaceuticals, Inc.

(Name of Issuer)

Common stock, par value $0.00001 per share

(Title of Class of Securities)

69353Y103

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

Sio Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,735,396.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,735,396.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,735,396.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.19 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: 1 As of June 30, 2025, Sio Capital Management, LLC beneficially owned 3,735,396 shares of Common Stock with shared voting power and shared dispositive power. 2 Based on 51,952,680 shares of common stock outstanding as of May 9, 2025, as reported in the Issuer's Form 10-K filed with the SEC on March 3, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PMV Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 400 Alexander Park Drive, Suite 301, Princeton, NJ, 08540
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of Sio Capital Management, LLC (the "Reporting Person" or "Sio") Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
(b)	Address or principal business office or, if none, residence: 600 Third Avenue, 2nd Floor New York, New York 10016
(c)	Citizenship: Sio is a Delaware limited liability company.
(d)	Title of class of securities: Common stock, par value $0.00001 per share
(e)	CUSIP No.: 69353Y103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,735,396
(b)	Percent of class: 7.19%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,735,396 - Refer to footnote 3
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,735,396 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sio Capital Management, LLC

Signature:	/s/ Jin W. Lee
Name/Title:	Chief Compliance Officer
Date:	08/13/2025

FAQ

How many PMVP shares does Sio Capital own?

Sio Capital beneficially owns 3,735,396 shares of PMV Pharmaceuticals common stock.

What percentage of PMVP does Sio Capital hold?

The filing reports a 7.19% stake based on 51,952,680 shares outstanding as reported by the issuer.

Does Sio Capital have sole voting power over its PMVP shares?

No. The filing shows 0 shares with sole voting power and 3,735,396 shares with shared voting power.

Are the shares held for activist purposes?

No. The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control.

Who else is referenced as potentially having influence over the shares?

The filing notes that Sio GP, LLC and Michael Castor may be deemed to have influence, but any such beneficial ownership is expressly disclaimed.